Breaking News

Celerion Celebrates 80th Anniversary

By Kristin Brooks | December 19, 2013

Lincoln, NE operations began as Harris Laboratories in 1933

Celerion is celebrating its 80th anniversary operating at its facility in Lincoln, NE. Celerion provides early clinical research services from seven facilities globally, with 950 employees and a 750-bed capacity. Celerion supports the development of experimental and currently marketed drugs, including agents that treat diabetes, hypertension, blood lipid disorders, obesity, gastrointestinal conditions, respiratory diseases, inflammation, pain neurologic disease, infections, and reproductive health.
The operations in Lincoln began in 1933, with legacy company Harris Laboratories, and focused on the science of food testing, analysis of water and animal feeds, and later, agricultural testing. The focus expanded to healthcare in 1969 by offering comprehensive clinical research services. Celerion was formed in 2010 through the acquisition of the early stage development operations of MDS Pharma Services. Prior to that, the facility in Lincoln conducted business under the name MDS Harris, following the acquisition by MDS Inc.
In addition to clinical studies, clinical pharmacology data analysis and reporting, along with a large bioanalytical lab, the facility now has an on-site ADME suite capable of handling radiotracers, a USP <797> Clean Room, and microdosing capabilities. Through an alliance with Bryan Health Hospital, which includes 24 on-site beds, provides access to their personnel and equipment, including MRI, PET scans, CT, EMG, EGD and CNS/cognitive testing.
“We are extremely proud of our 80-year heritage and the impact of our services globally,” said Susan Thornton Ph.D., president and chief executive officer of Celerion. “Harris Laboratories was visionary in developing innovative clinical research services for the pharmaceutical industry. Celerion continues this legacy in Applied Translational Medicine by leveraging our experience, expertise, innovative technologies and access to patients earlier in clinical research.”
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision